AtaiBeckley (FRA:B72) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B72 AtaiBeckley Inc FRA:B72
56 GF Score
Price €4.42
GF Value €6.00
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is AtaiBeckley SpecialCharges?

Special Charges only applies to banks.

FRA:B72
56GF Score
AtaiBeckley Inc FRA:B72
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AtaiBeckley (FRA:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €4.42 is trading 26.3% below its estimated GF Value™ of €6.00. GuruFocus considers AtaiBeckley to be Modestly Undervalued.

Key valuation signals for FRA:B72:

  • SpecialCharges:
  • GF Value™: €6.00 vs. price of €4.42 (26.3% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the FRA:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AtaiBeckley Business Description

Other Exchanges ATAI:USAB72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
56GF Score

Get the complete analysis for FRA:B72

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.42
Price
€6.00
GF Value